Seaport Therapeutics Secures $225 Million to Advance Mental Health Treatments
Seaport Therapeutics Secures $225 Million Financing Round
BOSTON -- Seaport Therapeutics, a clinical-stage biopharmaceutical company, has announced the successful closing of an oversubscribed $225 million Series B financing round. This substantial funding will support the company in advancing its innovative neuropsychiatric medicines.
Investors Backing Seaport Therapeutics
The financing efforts were spearheaded by General Atlantic, a prominent global growth investor. Notable participants include funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and additional new investors. Original backers such as ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also contributed to this round.
Significance of the Funding
This recent funding effort raises the total capital raised by Seaport to an impressive $325 million since its inception. The funds will primarily be utilized to propel the Company’s clinical-stage pipeline of medications toward significant milestones, as well as to expand the capabilities of the Glyph™ technology platform that has already shown clinical proof-of-concept.
Daphne Zohar's Vision for Mental Health
“We are deeply thankful for the opportunity to partner with this exceptional group of investors,” stated Daphne Zohar, Founder and CEO of Seaport Therapeutics. “Together, we aim to deliver superior medicines for individuals struggling with mental health conditions such as depression and anxiety. Our mission continues as we advance innovative therapeutics that deliver clinically proven outcomes, overcoming barriers that have previously restricted their development.”
Expert Insights into Seaport's Potential
Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic, expressed enthusiasm about the partnership. “We are extremely impressed with Seaport’s impressive CNS clinical track record and exceptional team. The setup for clinical development, combined with the innovative nature of the Glyph platform, signals a promising direction for the Company’s future,” noted Zbar.
Understanding the Glyph™ Technology Platform
The Glyph technology platform is a proprietary system that enhances drug absorption via the lymphatic system, enabling a more efficient route for oral drug delivery. This advancement minimizes first-pass metabolism and mitigates potential liver-related side effects that typically hinder many therapeutic candidates.
Seaport's Advanced Therapeutic Candidates
Among the leading candidates in the pipeline is SPT-300, an oral prodrug of allopregnanolone currently moving into a Phase 2b trial targeting major depressive disorder accompanied by or without anxious distress. Allopregnanolone is recognized for its rapid antidepressant and anxiolytic effects, and SPT-300 retains these benefits in an orally administered format.
SPT-320, another promising candidate, serves as a novel agomelatine prodrug entering Phase 1 trials for generalized anxiety disorder (GAD). This innovative approach leverages the Glyph platform to bypass the liver’s initial breakdown, potentially allowing lower dosages that reduce liver exposure while maintaining efficacy.
In addition to SPT-300 and SPT-320, Seaport is also developing SPT-348, distinguished by its non-hallucinogenic neuroplastogen properties, aimed at treating various mood and neuropsychiatric disorders. Multiple discovery and preclinical projects are also in progress to further enrich Seaport’s therapeutic landscape.
About Seaport Therapeutics
Seaport Therapeutics is dedicated to developing revolutionary neuropsychiatric medicines addressing critical gaps in patient care. With a robust strategy grounded in advanced mechanisms and the proprietary Glyph platform, the company is well-positioned to tackle medication challenges relating to bioavailability and side effects. Led by a highly experienced team and supported by a broad network of scientists and clinicians, Seaport is making strides toward better mental health solutions.
Frequently Asked Questions
What is the significance of Seaport's recent financing round?
The recent $225 million financing is crucial for advancing their neuropsychiatric medicine pipeline and expanding the capabilities of their unique Glyph technology.
Which investors participated in this financing round?
Notable investors include General Atlantic, T. Rowe Price Associates, and Goldman Sachs Alternatives, among others.
How does the Glyph platform benefit drug development?
The Glyph platform enhances oral drug availability and eliminates first-pass metabolism, thereby reducing side effects for better therapeutic outcomes.
What are some therapeutic candidates being developed by Seaport?
Seaport is advancing several candidates, including SPT-300 for major depressive disorder and SPT-320 for generalized anxiety disorder.
What is Seaport Therapeutics' mission?
The mission of Seaport Therapeutics is to advance effective neuropsychiatric medicines to meet the substantial unmet needs of patients suffering from mental health disorders.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- InterDigital Partners with UT Austin to Advance AI in Wireless Tech
- Niu Technologies Prepares to Release Q3 2024 Financials
- Innovative Partnership to Propel Sustainable Travel Forward
- Global Fashion Summit Debuts in China to Promote Sustainability
- Kepler's Forerunner K2: A Leap Towards Intelligent Robotics
- JD.com Stock Sees Upgrade from Loop Capital Amid Growth Prospects
- Volvo AB Stock Boosted by Stifel: 2025 Growth Anticipated
- Upcoming Economic Events: What to Watch in Market Shifts
- Evosep Relocates to New Headquarters to Empower Pharma Innovation
- Market Outlook: What to Expect This Week in Finance
Recent Articles
- Lazard Welcomes Fabien Antignac to Lead European Debt Solutions
- Great Bay Bio's Revolutionary Drug Development Ecosystem Unveiled
- Akkodis Achieves Zinnov Leader Status for Digital Engineering
- BWH Hotels and Mews: A Transformative Partnership for Innovation
- McDermott Achieves Platinum Status in Garnet Recycling Leadership
- Thunes Empowers Banks with Mobile Wallet Payment Solutions
- YogaEasy Unveils Exciting New Online Platform for Yoga Lovers
- Rockit Global's Partnership with Kung Fu Panda: A Delightful Venture
- Akkodis Awarded as Leader in ER&D and Digital Engineering
- Dr. Joleen Liang: Leading the AI Transformation in Education
- Tan Dun: Journey from Hunan Villager to Global Music Icon
- DNB's Strategic Acquisition of Carnegie Valued at $1.14 Billion
- Bitcoin Soars to $69K: Trump Speculation Fuels Cryptocurrency Rise
- Unlocking Financial Growth: Top ETFs for Lifelong Investments
- Insights from Fabricio Bloisi on Prosus' Vision and Growth
- ONWARD Medical Welcomes Industry Experts to Board Leadership
- Vallourec Partners with ASMO to Enhance Supply Chain Solutions
- Sanofi and CD&R Collaborate to Elevate Opella in Healthcare
- UBS Divests Swisscard Stake to American Express in Strategic Move
- Australian Stocks Surge: S&P/ASX 200 Sees Notable Gains
- Sanofi Negotiates Sale of Opella to Clayton Dubilier & Rice
- Virtualware Expands Horizons with Strategic Acquisition of Simumatik
- ONWARD Medical Welcomes New Leaders to its Board of Directors
- Vallourec and ASMO Form Game-Changing Alliance for Energy
- Sanofi and CD&R Partner to Elevate Opella in Consumer Health
- FORVIA Reports Q3 2024 Sales With Strong Growth Amid Challenges
- Cabka Reports Positive Q3 Sales Growth Amidst Challenges
- Boussard & Gavaudan Holding Limited Update on NAV Metrics
- Boussard & Gavaudan Holding Limited: Updated NAV Details
- Sampo plc Expands Share Buyback Program Amid Market Changes
- Thailand Sees Surge in Investment Applications Amid Tech Boom
- ARC Group: A Leader in Investment Advisory Services Industry
- Global Economic Outlook: IMF and World Bank Face Challenges
- Understanding the Dynamics of ASML and TSMC in Semiconductors
- Bigbank AS Secures Success with Unsecured Bond Offering
- VEON Achieves Compliance with Nasdaq After Recent 20-F Filing
- LHV Pank Expands Through Strategic Acquisition of Loans
- Galderma's Latest Findings Showcase RelabotulinumtoxinA Efficacy
- Trailstone and Eurowind Energy Collaborate to Boost Renewables
- VEON Achieves Nasdaq Compliance After 2023 20-F Filing Success
- AI Technology Expansion: Key Insights and Market Predictions
- Support for Pennsylvania Senate Candidates: Crypto's Influence
- Bitcoin Approaches $70,000 Amid Regulatory Optimism
- Sam Altman Chooses Mark Zuckerberg in Hypothetical Cage Match
- SAP's Earnings Report: Key Insights and Market Reactions
- Emerging Market Stocks' Growth Potential Amid Global Changes
- Gary Black Discusses Pragmatic Valuation for Tesla Growth
- Gold Prices Soar Amidst Market Turmoil and Political Uncertainty
- Malaysia's Q3 Economic Growth Insights and Future Projections
- Innovative Intranasal Vaccines by Blue Lake and CyanVac